Cutting edge: TRAIL deficiency accelerates hematological malignancies

Journal of Immunology

Volumn 175, Issue 9, 2005, Pages 5586-5590

  Zerafa, Nadeen ^a   Westwood, Jennifer A ^a   Cretney, Erika ^a   Mitchell, Sally ^a   Waring, Paul ^b   Iezzi, Manuela ^c   Smyth, Mark J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER MODEL; CARCINOGENESIS; CONTROLLED STUDY; EVALUATION; HEMATOLOGIC MALIGNANCY; LIFESPAN; LYMPHATIC SYSTEM TUMOR; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; STROMA; TUMOR SUPPRESSOR GENE;

EID: 27144489394     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.9.5586     Document Type: Article

References (24)

1. Ashkenazi, A., and V. M. Dixit. 1999. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11: 255-260.
2. Takeda, K., Y. Hayakawa, M. J. Smyth, N. Kayagaki, N. Yamaguchi, S. Kakuta, Y. Iwakuca, H. Yagita, and K. Okumura. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7: 94-100.
3. Smyth, M. J., E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to Interferon γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193: 661-670.
4. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, and N. A. Fanger. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189: 1343-1354.
5. Ludwig, A. T., J. M. Moore, Y. Luo, X. Chen, N. A. Saltsgaver, M. A. O'Donnell, and T. S. Griffith. 2004. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette- Guérin-induced antitumor activity. Cancer Res. 64: 3386-3390.
6. + T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-α on APO2L/TRAIL expression and -mediated cytotoxicity. J. Immunol. 169: 809-817.
7. Smyth, M. J., K. Takeda, Y. Hayakawa, J. J. Peschon, M. R. van den Brink, and H. Yagita. 2003. Nature's TRAIL-on a path to cancer immunothetapy. Immunity 18:1-6.
8. Sedger, L. M., M. B. Glaccum, J. C. Schuh, S. T. Kanaly, E. Williamson, N. Kayagaki, T. Yun, P. Smolak, T. Le, R. Goodwin, and B. Gliniak. 2002. Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32: 2246-2254.
9. Cretney, E., K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth. 2002. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168: 1356-1361.
10. Takeda, K., M. J. Smyth, E. Cretney, Y. Hayakawa, N. Yamaguchi, H. Yagita, and K. Okumura. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-γ-dependent suppression of subcutaneous tumor growth. Cell. Immunol. 214: 194-200.
11. Schmaltz, C., O. Alpdogan, B. J. Kappel, S. J. Muriglan, J. A. Rotolo, J. Ongchin, L. M. Willis, A. S. Greenberg, J. M. Eng, J. M. Crawford, et al. 2002. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8: 1433-1437.
12. Takeda, K., M. J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagira, and K. Okumura. 2002. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195: 161-169.
13. Yue, H. H., G. E. Diehl, and A. Winoto. 2005. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ. 12: 94-97.
14. Boggio, K., E. Di Carlo, S. Rovero, F. Cavallo, E. Quaglino, P. L. Lollini, P. Nanni, G. Nicoletti, S. Wolf, P. Musiani, and G. Forni. 2000. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res. 60: 359-364.
15. Smyth, M. J., K. Y. Thia, S. E. Street, D. MacGregor, D. I. Godfrey, and J. A. Trapani. 2000. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192: 755-760.
16. Street, S. E., J. A. Trapani, D. MacGregor, and M. J. Smyth. 2002. Suppression of lymphoma and epithelial malignancies effected by Interferon γ. J. Exp. Med. 196: 129-134.
17. Pupa, S. M., M. Iezzi, E. Di Carlo, A. Invernizzi, F. Cavallo, R. Meazza, A. Comes, S. Ferrini, P. Musiani, and S. Menard. 2005. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res. 65: 1071-1078.
18. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockerr, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95: 7556-7561.
19. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
20. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
21. Smyth, M. J., K. Y. Thia, S. E. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. Kawano, S. B. Pelikan, N. Y. Crowe, and D. I. Godfrey. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191: 661-668.
22. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434: 88-93.
23. Neville-Webbe, H. L., N. A. Cross, C. L. Eaton, R. Nyambo, C. A. Evans, R. E. Coleman, and I. Holen. 2004. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res. Treat 86: 269-279
24. Katz, E., M. H. Lareef, J. C. Rassa, S. M. Grande, L. B. King, J. Russo, S. R. Ross, and J. G. Monroe. 2005. MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture. J. Exp. Med. 201: 431-439.